Compare SPRO & BOF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SPRO | BOF |
|---|---|---|
| Founded | 2013 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Packaged Foods |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 71.6M | 63.6M |
| IPO Year | 2017 | 2023 |
| Metric | SPRO | BOF |
|---|---|---|
| Price | $1.20 | $3.98 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 1.5M | 21.0K |
| Earning Date | 05-13-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 111.81 | 31.33 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $66,802,000.00 | $3,184,018.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $300.00 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 39.24 | ★ 258.20 |
| 52 Week Low | $1.08 | $1.93 |
| 52 Week High | $3.08 | $5.25 |
| Indicator | SPRO | BOF |
|---|---|---|
| Relative Strength Index (RSI) | 31.16 | 44.61 |
| Support Level | $1.10 | $2.86 |
| Resistance Level | $1.28 | $4.29 |
| Average True Range (ATR) | 0.06 | 0.24 |
| MACD | 0.04 | -0.01 |
| Stochastic Oscillator | 40.00 | 16.69 |
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
Branchout Food inc is engaged in the development, marketing, sale, and distribution of plant-based, dehydrated fruit and vegetable snacks and powders. Its products are currently manufactured for the company by contract manufacturers based in South America and North America that produce dehydrated fruit and vegetable products for the company using a new proprietary dehydration technology that it licenses from a third party. The Company's customers are located throughout the United States. Its current primary products are BranchOut Snacks, BranchOut Powders, and BranchOut Industrial Ingredients. The products are mainly sold through three channels: branded retail snack products, private label products for retailers, and fruit and vegetable ingredients sold to food manufacturers.